INDIA MARKET LENS

Abbott India Limited (ABBOTINDIA): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Abbott India Limited, explained in plain English.

  • Abbott India Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • ABBOTINDIA closed at ₹25,695.00 on 19 November 2026.
  • Over the past year the shares are down 13.0%, trading between ₹24,650.00 and ₹30,655.00.
  • Reported fundamentals show return on equity of 39.92%, a net margin of 22.96%, debt to equity of 3.61.
  • Our Pulse grade checklist scores it C (64/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
  • Annualised volatility over the past year is 21.55% with a maximum drawdown of -17.13% and a beta of 0.21 against NIFTY 50.
  • Recent coverage: Q2 Results Live Updates: LG Electronics, Bharti Airtel, Abbott India, Astral, Bharat Forge, Berger Paints, Emami, Fortis Healthcare Earnings In Focus

Other Pharma & Healthcare companies: Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma, Biocon

Last traded values from 19 Nov 2026. Market opens at 9:15 IST.

Abbott India Limited (ABBOTINDIA)

₹25,470

▼ 345 (-1.34%)

Price & volume

ABBOTINDIA price chart, 1Y range. 252 points from 2025-11-19 to 2026-11-18. Opens at 29,530, closes at 25,470, ranging between 25,030 and 30,205.26,00028,00030,000Nov-25Jan-26Mar-26Apr-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Weak momentum · 0/5
✕ Above 50-day avg✕ Above 200-day avgRSI 42.5 · healthyMACD negativeBollinger %B 24ADX 15.9 · weak trend

1M

-2.67%

3M

-4.18%

6M

-8.79%

1Y

-14.14%

Where it sits in its 52-week range

9%
₹25,030₹30,205

Below 52-week high

15.7%

1.8% above the low

Momentum read

Weak

0/5 checks passed

52-wk high

₹30,205

52-wk low

₹25,030

Market cap

₹54,122 Cr

P/E (trailing)

32.7

Dividend yield

—

ROE

39.92%

Profit margin

22.96%

Revenue growth

11%

Price / Book

12.67

Debt / Equity

3.61

EPS (TTM)

777.81

Book value

₹2009.52

Beta

0.21

Pulse grade: C, 56 out of 100

Momentum

F
  • ✕Trading above 50-day average
  • ✕Trading above 200-day average
  • ✕RSI in healthy 45-70 zone
  • ✕Positive 3-month return

Growth

C
  • ✕Revenue growth above Pharma & Healthcare median (20.8%)
  • ✓Revenue growing above 5%
  • ✓Quarterly profits trending up

Profitability

A
  • ✓Return on equity above Pharma & Healthcare median (14.56%)
  • ✓Return on equity above 12%
  • ✓Profit margin above Pharma & Healthcare median (13.82%)

Safety

A
  • ✓Debt below Pharma & Healthcare median (18.57)
  • ✓Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹1,951 crore · net profit ₹453 crore · margin 23.2%

1,9510Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,871.5+0.08%-6.48%
DRREDDY1,398.2+0.73%0.00%
CIPLA1,417+2.09%-7.46%
DIVISLAB11,049-0.91%-4.47%
APOLLOHOSP8,821+1.25%-2.73%
LUPIN1,971.9+1.12%-21.59%

ABBOTINDIA headlines

No ABBOTINDIA stories right now.

ABBOTINDIA filings & announcements

Reading the exchange…

ABBOTINDIA, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

21.53%

Sharpe ratio

-0.88

Sortino ratio

-1.31

Max drawdown

-17.13%

Daily VaR (95%)

-1.95%

CAGR (1Y)

-13.8%

Return skew

0.82

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.